A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
Completed · Phase 3 · NCT00174785
Conditions: Atrial Fibrillation, Atrial Flutter
At a glance
- Research payments reported, 2025
- $1,250
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 4,628
About the trial
- Sponsor
- Sanofi
- Tested
- dronedarone (SR33589) (drug), placebo (drug)
- Dates
- Started 2005-06; completion 2008-03
- Results posted
- Yes
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL). To assess that dronedarone is well tolerated in this population.
From ClinicalTrials.gov, last updated 2010-01-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi-aventis U.S. LLC reported $1,250 in research payments for this study in 2025 (1 payments).
Products named: Multaq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $1,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.